A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
Arthritis Rheumatol 2016;68:2867–77
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Arthritis Rheumatol 2016;68:2867–77
Arthritis Rheumatol 2016;68:2857–66
Arthritis Rheumatol DOI 10.1002/art.40054. Accepted article.
Arthritis Rheumatol 2017. DOI 10.1002/art.40036.
Clin Ther 2016;38:2628–40.
Arthritis & Rheum 2016; ePub ahead of print
Ann Rheum Dis 2016;75:1979–83
Arthritis Rheumatol 2016; Accepted article DOI 10.1002/art-39808 [Epub 2016]
Ann Rheum Dis. 2016 Jun;75:1057-64. doi: 10.1136/annrheumdis-2015-208279. Epub 2015 Dec 15
J Rheumatol. 2016;43(3):504–511.